Literature DB >> 30531622

Analysis of Keloid Response to 5-Fluorouracil Treatment and Long-Term Prevention of Keloid Recurrence.

Ryan LaRanger1, Anis Karimpour-Fard1, Christopher Costa1, David Mathes1, Woodring E Wright1, Tae Chong1.   

Abstract

Keloids are benign fibroproliferative skin tumors that can cause disfigurement and disability. Although they frequently recur after excision or medical management and can affect 6 to 16 percent of African Americans, there is no gold standard therapy. Keloids are challenging to study because there are no animal or in vitro models of this disorder. This makes it very difficult to validate data from treated tissue samples or cells and develop targeted therapies for this disease. In this study, the authors demonstrate that intralesional 5-fluorouracil injection after keloid excision prevents recurrence for 2 years, with no reported adverse events. The authors analyze the expression of treated and untreated biopsy specimens of the same keloids in their native context to capture insights that may be missed by in vitro cell culture models and correct for intrakeloid variability. Random forest analysis of the microarray data dramatically increased the statistical power of the authors' results, permitting hypothesis-free creation of a gene expression profile of 5-fluorouracil-treated keloids. Through this analysis, the authors found a set of genes, including YAP1 and CCL-2, whose expression changes predict 5-fluorouracil therapy status and include genes that have not previously been associated with keloid biology and are of unknown function. The authors further describe keloid heterogeneity for the first time using multidimensional analysis of their microarray results. The methods and tools the authors developed in this research may overcome some of the challenges in studying keloids and developing effective treatments for this disease. CLINICAL QUESTION/LEVEL OF EVIDENCE:: Therapeutic, V.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30531622      PMCID: PMC6349497          DOI: 10.1097/PRS.0000000000005257

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  23 in total

1.  Keloid-derived keratinocytes exhibit an abnormal gene expression profile consistent with a distinct causal role in keloid pathology.

Authors:  Jennifer M Hahn; Kathryn Glaser; Kevin L McFarland; Bruce J Aronow; Steven T Boyce; Dorothy M Supp
Journal:  Wound Repair Regen       Date:  2013 Jul-Aug       Impact factor: 3.617

2.  Microarray as a new tool to study hypertrophic and keloid scarring.

Authors:  Maria Luiza Ramos; Alfredo Gragnani; Lydia Masako Ferreira
Journal:  Wounds       Date:  2009-02       Impact factor: 1.546

Review 3.  Standard guidelines of care: Keloids and hypertrophic scars.

Authors:  Somesh Gupta; V K Sharma
Journal:  Indian J Dermatol Venereol Leprol       Date:  2011 Jan-Feb       Impact factor: 2.545

4.  IL-17 promotes immune privilege of corneal allografts.

Authors:  Khrishen Cunnusamy; Peter W Chen; Jerry Y Niederkorn
Journal:  J Immunol       Date:  2010-09-15       Impact factor: 5.422

5.  Transforming Growth Factor-β and Interleukin-1β Signaling Pathways Converge on the Chemokine CCL20 Promoter.

Authors:  Oliver J Brand; Sangeeta Somanath; Catherine Moermans; Haruhiko Yanagisawa; Mitsuo Hashimoto; Stephanie Cambier; Jennifer Markovics; Andrew J Bondesson; Arthur Hill; David Jablons; Paul Wolters; Jianlong Lou; James D Marks; Jody L Baron; Stephen L Nishimura
Journal:  J Biol Chem       Date:  2015-04-27       Impact factor: 5.157

Review 6.  YAP/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth.

Authors:  Boon Chuan Low; Catherine Qiurong Pan; G V Shivashankar; Alexander Bershadsky; Marius Sudol; Michael Sheetz
Journal:  FEBS Lett       Date:  2014-04-18       Impact factor: 4.124

7.  Bioengineered Models of Solid Human Tumors for Cancer Research.

Authors:  Alessandro Marturano-Kruik; Aranzazu Villasante; Gordana Vunjak-Novakovic
Journal:  Methods Mol Biol       Date:  2016

8.  An abnormality in glucocorticoid receptor expression differentiates steroid responders from nonresponders in keloid disease.

Authors:  D Rutkowski; F Syed; L C Matthews; D W Ray; D A McGrouther; R E B Watson; A Bayat
Journal:  Br J Dermatol       Date:  2015-07-28       Impact factor: 9.302

9.  Functional analysis of keratinocyte and fibroblast gene expression in skin and keloid scar tissue based on deviation analysis of dynamic capabilities.

Authors:  Mingming Li; Lei Wu
Journal:  Exp Ther Med       Date:  2016-10-18       Impact factor: 2.447

Review 10.  The Use of Chemotherapeutics for the Treatment of Keloid Scars.

Authors:  Christopher David Jones; Luke Guiot; Mike Samy; Mark Gorman; Hamid Tehrani
Journal:  Dermatol Reports       Date:  2015-05-21
View more
  5 in total

1.  Exosomes released by melanocytes modulate fibroblasts to promote keloid formation: a pilot study.

Authors:  Zeren Shen; Jinjin Shao; Jiaqi Sun; Jinghong Xu
Journal:  J Zhejiang Univ Sci B       Date:  2022-08-15       Impact factor: 5.552

2.  Downregulation of PLK4 expression induces apoptosis and G0/G1-phase cell cycle arrest in keloid fibroblasts.

Authors:  Ru-Lin Huang; Chuanqi Liu; Rao Fu; Yuxin Yan; Jing Yang; Xinggang Wang; Qingfeng Li
Journal:  Cell Prolif       Date:  2022-06-07       Impact factor: 8.755

3.  Artificial Intelligence in Pharmacoepidemiology: A Systematic Review. Part 1-Overview of Knowledge Discovery Techniques in Artificial Intelligence.

Authors:  Maurizio Sessa; Abdul Rauf Khan; David Liang; Morten Andersen; Murat Kulahci
Journal:  Front Pharmacol       Date:  2020-07-16       Impact factor: 5.810

Review 4.  The role of pharmacogenetics in keloid scar treatment: A literature review.

Authors:  Tamara Searle; Faisal R Ali; Firas Al-Niaimi
Journal:  Scars Burn Heal       Date:  2020-08-13

5.  A selective small-molecule inhibitor of c-Met suppresses keloid fibroblast growth in vitro and in a mouse model.

Authors:  Min-Ha Choi; Jinhyun Kim; Jeong Hyun Ha; Ji-Ung Park
Journal:  Sci Rep       Date:  2021-03-09       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.